39
Participants
Start Date
August 30, 2011
Primary Completion Date
December 12, 2011
Study Completion Date
December 12, 2011
SRT2379
SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
Placebo
For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
GSK Investigational Site, Amsterdam
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Sirtris, a GSK Company
INDUSTRY